The success of Viagra initially sparked a period of growth for the drug industry, nevertheless recent shifts present a complicated picture for shareholders. Lower-cost alternatives are eroding profits, and ongoing litigation add further risk to the landscape. While specific companies could still gain from complementary products, the overall directi